Follow the Latigo Biotherapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1.5bn. The latest transaction was disclosed on 12 August 2026 (C). Among the most active insiders: Foresite Capital Management V, LLC. Every trade is accessible without an account.
34
Insider Decl.
n/a
Thresholds
€4m
2 ops.
Buy Volume
n/a
n/a
Sell Volume
29Σ signal
Buys €4mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Latigo Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases. It is listed on NASDAQ under the ticker symbol XNAS.